氟替卡松

维基百科中的醫學内容仅供参考，並不能視作專業意見。如需獲取醫療幫助或意見，请咨询专业人士。詳見醫學聲明。
提示：此条目的主题不是氟康唑。
氟替卡松
臨床資料
AHFS/Drugs.comMonograph
懷孕分級
  • C(鼻腔內吸入)
给药途径鼻腔內吸入，局部塗搽
ATC碼
法律規範狀態
法律規範
藥物動力學數據
生物利用度0.51% (鼻腔內)
血漿蛋白結合率91%
药物代谢鼻腔內
肝臟(CYP3A4-中介)
生物半衰期10小時
排泄途徑腎臟
识别信息
  • S-(fluoromethyl) (6S,8S,9R,10S,11S,13S,14S,16R,17R)-
    6,9-difluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-
    6,7,8,11,12,14,15,16-octahydrocyclopenta[a]
    phenanthrene-17-carbothioate
CAS号80474-14-2（（丙酸酯））  checkY
90566-53-3  checkY
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard（英语：CompTox Chemicals Dashboard） (EPA)
化学信息
化学式C22H27F3O4S
摩尔质量444.508 g/mol
3D模型（JSmol（英语：JSmol））
  • O=C(SCF)[C@]3(O)[C@]2(C[C@H](O)[C@]4(F)[C@@]/1(\C(=C/C(=O)\C=C\1)[C@@H](F)C[C@H]4[C@@H]2C[C@H]3C)C)C
  • InChI=1S/C22H27F3O4S/c1-11-6-13-14-8-16(24)15-7-12(26)4-5-19(15,2)21(14,25)17(27)9-20(13,3)22(11,29)18(28)30-10-23/h4-5,7,11,13-14,16-17,27,29H,6,8-10H2,1-3H3/t11-,13+,14+,16+,17+,19+,20+,21+,22+/m1/s1 checkY
  • Key:MGNNYOODZCAHBA-GQKYHHCASA-N checkY

氟替卡松（英語：fluticasone）為一種綜合的糖皮质激素。[1]

與糠酸酯（furoate）或丙酸酯（propanoate)的合成品可以用為局部抗炎性、比如鼻炎方面：[2]

參見

註釋

  1. ^ Briggs, Gerald G.; Freeman, Roger K.; Yaffe, Sumner J., Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk, Lippincott Williams & Wilkins: 600, 2012 [2013-10-28], ISBN 1451153597, （原始内容存档于2014-01-01）. 
  2. ^ Spratto, George R.; Woods, Adrienne L., Delmar Nurse's Drug Handbook 2012, Cengage Learning: 748, 2012 [2013-10-28], ISBN 1111310653, （原始内容存档于2014-01-01）. 

參考文獻

  • Jarvis B., Faulds D. (1999): Inhaled fluticasone propionate: A review of its therapeutic efficacy at dosages < or = 500 microg/day in adults and adolescents with mild to moderate asthma. Drugs, 57(5), 769–803. PMID 10353302
  • Johnson M. (1995): The anti-inflammatory profile of fluticasone propionate. Allergy, 50(23), 11–14. PMID 7604948
  • Keating G.M., McCormack P.L. (2007): Salmeterol/fluticasone propionate: a review of its use in the treatment of chronic obstructive pulmonary disease. Drugs, 67(16), 2383–2405. PMID 17983257
  • Reynolds N.A., Lyseng-Williamson K.A., Wiseman L.R. (2005): Inhaled salmeterol/fluticasone propionate: a review of its use in asthma. Drugs, 65(12), 1715–1734. PMID 16060707
  • Spencer C.M., Jarvis B. (1999): Salmeterol/fluticasone propionate combination. Drugs, 57(6), 933–940. PMID 10400406
  • Staresinic A.G., Sorkness C.A. (2000): Fluticasone propionate: A potent inhaled corticosteroid for the treatment of asthma. Expert Opin Pharmacother, 1(6), 1227-1244. PMID 11249490
  • Avamys, Zusammenfasuung der Merkmale des Arzneimittels (PDF; 440 kB), Stand Dezember 2012, Europäische Arzneimittelagentur.